# Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

> **NCT04265274** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute, Slovakia**

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Disulfiram
- **DRUG:** Vinorelbin
- **DRUG:** Cisplatin
- **DRUG:** Copper

## Key facts

- **NCT ID:** NCT04265274
- **Lead sponsor:** National Cancer Institute, Slovakia
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-01-01
- **Primary completion:** 2022-01-01
- **Final completion:** 2023-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Poor acrual
- **Last updated:** 2023-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04265274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04265274, "Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04265274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*